Neuphoria Therapeutics (NEUP) Interest & Investment Income (2023 - 2026)
Neuphoria Therapeutics (NEUP) reported Interest & Investment Income of $186171.0 for Q1 2026, up 1361.2% year-over-year from $12741.0 in Q1 2025, and up 11.27% on a QoQ basis from $167311.0 in Q4 2025.
Neuphoria Therapeutics (NEUP) has 4 years of Interest & Investment Income data on file, last reported at $186171.0 in Q1 2026.
- Quarterly Interest & Investment Income rose 1361.2% year-over-year to $186171.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $582524.0 (up 450.7% YoY) and the FY2025 annual result came in at $166498.0, down 24.35% from the prior year.
- Interest & Investment Income climbed to $186171.0 in Q1 2026 per NEUP's latest filing, from $167311.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $186171.0 in Q1 2026 and bottomed at $12741.0 in Q1 2025.
- The 4-year median for Interest & Investment Income is $54716.0 (2023), against an average of $80188.5.
- The widest annual swing landed in 2025, when Interest & Investment Income plunged 75.78%; it then surged 1361.2% in 2026.
- Tracing NEUP's Interest & Investment Income over 4 years: stood at $54716.0 in 2023, then slumped by 44.05% to $30615.0 in 2024, then soared by 446.5% to $167311.0 in 2025, then gained by 11.27% to $186171.0 in 2026.
- Per Business Quant, the three latest NEUP Interest & Investment Income figures stand at $186171.0 (Q1 2026), $167311.0 (Q4 2025), and $141996.0 (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 7.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 114.80 Mn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 305,000.00 |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 26.60 Mn |
| 10 | Neuphoria Therapeutics | 28.35 Mn | 8.95 Mn | - | 186,171.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 186,171.00 |
| Dec 31, 2025 | 167,311.00 |
| Sep 30, 2025 | 141,996.00 |
| Jun 30, 2025 | 87,046.00 |
| Mar 31, 2025 | 12,741.00 |
| Dec 31, 2024 | 30,615.00 |
| Sep 30, 2024 | 36,096.00 |
| Jun 30, 2024 | 26,327.00 |
| Mar 31, 2024 | 52,615.00 |
| Dec 31, 2023 | 54,716.00 |
| Sep 30, 2023 | 86,439.00 |